INTRODUCTION
Acromegaly is a rare, serious, multisystem disease HORMONES 2017, 16 (1) : [84] [85] [86] [87] [88] [89] [90] [91] resulting from increased growth hormone (GH) secretion due in most cases to a pituitary adenoma, 1 with subsequent increases in insulin-like growth factor 1 (IGF-1) levels. Patients with active disease have higher morbidity and mortality than the general population. 2 The goals of treatment are to control the levels of both GH and IGF-1, reduce and/or stabilize tumour size, preserve pituitary function and prevent recurrence.
Transsphenoidal surgery is generally recommended as first-line therapy. 4 However, even in referral centres, approximately 50% of the patients will experience persistent or recurrent disease and require medical treatment to achieve disease control. 5 Long-acting somatostatin analogues are the cornerstone of medical therapy for acromegaly and are indicated in patients with failed surgery or as first-line treatment when surgery is contraindicated or declined. 4 However, many patients do not achieve biochemical control with the somatostatin receptor subtype sst-2 preferential analogues octreotide and lanreotide. [6] [7] [8] Pasireotide is a multireceptor-targeted somatostatin analogue with high affinity for sst2, sst3 and sst5. 9 In a large randomized Phase III study in patients with medically naïve acromegaly, long-acting pasireotide was significantly superior to long-acting octreotide in providing biochemical control at month 12 (a head to-head superiority study). 10 In a second randomized Phase III study evaluating long-acting pasireotide versus long-acting octreotide or lanreotide autogel in somatostatin analogue-resistant patients with acromegaly (PAOLA study), pasireotide provided superior efficacy compared with continued treatment with octreotide or lanreotide for 24 weeks. 11 We report our experience with two patients enrolled in these studies who switched from octreotide to pasireotide during a crossover extension phase and who overresponded to pasireotide. The sst profile of these two somatotropinomas was analyzed. Patient 1 adenoma was immunostained for the different ssts using antibodies against sst2a (Zytomed; dilution, 1:150), sst3 (provided by S. Schulz, Jena, Germany; dilution, 1:10) and sst5 (Zytomed; dilution, 1:150). The sst 1, 2, 3 and 5 mRNA expression of patient 2 adenoma was measured by real-time RT-PCR and compared with the median of 23 other GH-adenomas evaluated at the same time, as previously published.
METHODS
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CASE 1
In November 2008, a 59-year-old female presented with characteristic features of acromegaly including enlarged face and hands, macroglossia, snoring and operations for bilateral carpal tunnel syndrome. She had previously undergone thyroid surgery for retrosternal goitre and resection of the parathyroid gland for primary hyperparathyroidism with severe hypercalcaemia. She was treated with thyroid hormone replacement therapy (100 μg/day) and metformin (850 mg/day) for type 2 diabetes mellitus. Genetic studies were negative for multiple endocrine neoplasia types 1 and 4.
Hormonal evaluation showed elevated levels of serum GH (>40 μg/L), IGF-1 (124-127 nmol/L; normal, 10.5-29.2), parathyroid hormone (98 ng/L; normal, 10-65) and serum calcium (10.9-11.2 mg/dL; normal, 8.5-10.5). Prolactin (PRL) levels were normal. Sellar magnetic resonance imaging (MRI) demonstrated a left pituitary macroadenoma (15×11 mm) with left cavernous sinus involvement but without suprasellar extension. A diagnosis of GH-secreting adenoma was suspected. In June 2009, the patient underwent transsphenoidal surgery and the adenoma was partially resected; immunostaining of the tumour showed both GH and PRL expression. Post-operative hormonal evaluation showed active acromegaly with elevated GH (16-21 μg/L) and IGF-1 (73 nmol/L) levels.
Medical therapy with a somatostatin analogue was offered within the Phase III clinical trial of longacting pasireotide versus long-acting octreotide. In August 2010, after 12 months the patient was switched to pasireotide, because of inadequate biochemical control as per study protocol, and was started on treatment with pasireotide 40 mg/month. After 3 months of treatment, GH and IGF-1 levels decreased to 0.8 μg/L and 9.6 nmol/L, respectively. The patient continued with the same pasireotide dose and IGF-1 levels were maintained below the lower limit of normal (LLN; Figure 2 ). After 12 months of pasireotide treatment, MRI revealed further tumour volume reduction (5×4.5 mm; Figure 1D ). Following the initiation of pasireotide treatment, HbA1c levels increased to 7.5% after 3 months. The addition of sitagliptin (100 mg/day) and glimepiride (1 mg/day) to metformin therapy resulted in a decrease in HbA1C levels to 6.4-6.6%.
After 18 months of pasireotide treatment, the dose was decreased to 20 mg/month. GH increased slightly from 0.6-0.9 μg/L to 1.4-1.7 μg/L, while IGF-1 levels increased from <LLN to within the normal range ( Figure 2 ). The patient continued to receive pasireotide 20 mg/month for a further 40 months. Long-term treatment with pasireotide also led to improvements in enlarged face and hands and snoring. At the last follow-up (month 70), MRI showed only a small tumour remnant and laboratory analysis indicated control of GH and IGF-1 levels, 07-0.8 μg/L and 11.4-15.3 nmol/L, respectively. Serum calcium was 10.9 mg/dL. HbA1c levels were well controlled (5.8%) with metformin 1700 mg/day, sitagliptin 100 mg/day and glimepiride 2 mg/day. The patient did not experience any other adverse events during treatment.
Immunostaining for Somatostatin receptors
The adenoma was immunostained for antibodies against sst2a, sst3 and sst5 and showed moderate membranous expression of somatostatin receptors sst2a and sst5 ( Figure 3 ) and no sst3 expression.
CASE 2
In 2008, a 28-year old female presented with hands and feet enlargement, hyperhidrosis, polyarthralgia, paresthesia, headache, snoring and characteristic acromegalic appearance.
Hormonal evaluation showed elevated baseline and nadir GH on oral glucose tolerance test (53.9 and 34.2 μg/L, respectively) and high IGF-1 (968 μg/L, normal 117-321) (Figure 4) . Prolactin, free T4 and cortisol levels were normal. Glucose was 85 mg/dL. MRI depicted a right intra and suprasellar mass with 21×17×19 mm ( Figure 5A ). (Figure 4 ). MRI showed a right-sided tumour remnant ( Figure  5B ). Octreotide 30 mg was reintroduced and after 6 months GH and IGF-1 were 4.9 μg/L and 355 μg/L (normal, 87-238). Cabergoline (up to 2.5 mg/week) was added with partial control (GH, 0.8 μg/L; IGF-1, 334 μg/L) (Figure 4) .
The patient was enrolled in a Phase III clinical trial (PAOLA study) evaluating pasireotide long-acting versus long-acting octreotide or lanreotide Autogel in somatostatin analogue-resistant patients. 11 At baseline, GH and IGF-1 levels were 3.2 μg/L and 434 μg/L (normal, 115-307), respectively. During the core phase, the patient was assigned to continue treatment with octreotide for 6 months with no change in GH and IGF-1 levels (GH, 3.3 μg/L and IGF-1, 392 μg/L). During the extension phase, the patient was allowed to switch to pasireotide 40 mg as per protocol and after 3 months GH and IGF-1 were normalized (GH, 1.1 μg/L; IGF-1, 151 μg/L). Continued treatment led to a further reduction in IGF-1 levels to below the LLN (80 and 72 μg/L), so pasireotide dose was reduced to 20 mg with normalization of IGF-1 levels (125 and 115 μg/L) (Figure 4 ). Tumour volume was reduced by approximately 30% during pasireotide treatment ( Figure 5D ). Before pasireotide treatment, glucose and HbA1c levels were 93 mg/dL and 5.1%, respec- tively. There was a mild increase in these parameters to 111 mg/dL and 6.2%, respectively, after 6 months of pasireotide treatment. At this time, the patient was oriented with respect to lifestyle changes (diet and exercises) and improved HbA1c to 5.7%.
Somatostatin receptors expression
Somatostatin receptors mRNA expression was evaluated by real-time RT-PCR and compared with the median of 23 other GH-adenomas evaluated at the same time. sst1, 2, 3 and 5 were 4.7, 1.1, 15.8 and 2.8 times the median of the 23 somatotropinomas cohort (Table 1) .
DISCUSSION
Acromegaly is a rare disease with an estimated prevalence of 40-124 cases/million and is associated with increased morbidity and mortality. 13 Normalization of GH and IGF-1 can restore mortality levels to that of the general population 2 Somatostatin analogues have been shown to control GH and IGF-1, achieve tumour volume reduction and improve cardiovascular comorbidities in these patients. 8, 14 However, many patients fail to achieve biochemical control with somatostatin analogues. 15 Pegvisomant is useful in patients who are inadequately controlled by somatostatin analogues, A Figure 4 . Pasireotide suppressed GH (A) and IGF-1 (B) in patient 2 resistant to multiple treatment regimens. The patient treated with long-acting octreotide, underwent transsphenoidal surgery (TSS) and was given combination therapy with octreotide and cabergoline (CAB) without biochemical control. After switching to pasireotide 40 mg/month, IGF-1 decreased to levels below the LLN, which resolved after dose decrease to 20 mg. The dashed lines represent the ULN for GH and the controlled range for IGF-1 during the PAOLA study. either as monotherapy or in combination. Although it has been shown to normalize IGF-1 levels in 63% of patients, pegvisomant has no effect on pituitary tumour volume. 16 Here we report two unique patients with acromegaly who were uncontrolled with octreotide and, when switched to pasireotide, suppressed IGF-1 to below the LLN and required reduction of pasireotide to the minimal dose. Patient 1 was one of 182 patients naïve to medical treatment (80 of whom had undergone prior surgery) who received long-acting octreotide in the 12-month core phase of a randomized doubleblind clinical trial. During the core study, long-acting pasireotide patients were more likely than octreotide patients to achieve biochemical control at month 12, with a higher rate of IGF-1 normalization (38.6% versus 23.6%; P=0.002). 10 This difference could be in part due to pasireotide having a higher affinity for sst5 than octreotide. Following treatment with octreotide and despite up-titration to 30 mg, this patient did not achieve biochemical control. The patient was one of 81 patients who subsequently switched to pasireotide at month 12, and 17 (21%) of these patients achieved biochemical control after switching to pasireotide, whereas only one (2.6%) of the 38 patients switching to octreotide LAR achieved biochemical control. 17 Following crossover to pasireotide, the patient's IGF-1 level was below the LLN and led to dose reduction. Long-term treatment with the reduced dose resulted in IGF-1 levels just above the LLN.
A recent 24-week Phase III study has evaluated long-acting pasireotide versus continued treatment with long-acting octreotide or lanreotide Autogel (active control) in patients with inadequately controlled acromegaly. 11 More patients treated with pasireotide achieved biochemical control (15.4% and 20.0% vs. 0%; P=0.0006 and P<0.0001, respectively) and tumour volume reduction >25% (18.5% and 10.8% vs. 1.5%) versus active control at 24 weeks.
11 Patient 2 was one of the 68 patients randomly assigned to continue treatment with long-acting octreotide or lanreotide Autogel for 24 weeks. The patient did not achieve biochemical control and was one of the 50 uncontrolled patients switched to pasireotide 40 mg as per study protocol. At extension week 28, 20% of patients in the crossover group had biochemical control, some after dose escalation to 60 mg. 18 Following crossover to pasireotide, the patient's IGF-1 level was below the LLN, similarly to patient 1, and required a dose reduction to 20 mg that still resulted in low IGF-1 levels, just above the LLN.
The pituitary adenomas resected during surgery were studied for the expression of ssts. In tumour 1 moderate staining for sst2 and sst5 was recorded (Figure 3 ). For tumour 2 the mRNA expression of sstr1, 3 and 5 was higher compared to the average in 23 other somatotropinomas (Table 1) . Octreotide through receptor binding to sst2 moderately suppressed GH and IGF-1 levels in both patients. Switching to pasireotide improved hormonal control, suppressing GH and IGF-1 to the normal range, and even below the LLN. Pasireotide, which has higher affinity for sst5 and slightly lower affinity for sst2 than octreotide, was superior to octreotide in both patients. As both adenomas showed expression of sst2, the superiority of pasireotide over octreotide in hormonal suppression may be explained by an intracellular sub-receptor mechanism other than receptor abnormality.
Hyperglycaemia has previously been reported in patients receiving pasireotide, 19 and following the switch to long-acting pasireotide both patients had some increase in glucose levels which were controlled with additional antidiabetic treatments in patient 1 and without medication in patient 2. Glucose homeostasis should be monitored carefully in patients receiving pasireotide and appropriate treatment initiated if glucose levels increase. 20 In conclusion, following crossover from octreotide to pasireotide, our patients achieved long-term biochemical control, tumour volume reduction and improvement in the clinical signs and symptoms of acromegaly. Moreover, a reduction of pasireotide dose was possible due to IGF-1 over-suppression. Pasireotide-associated hyperglycaemia was appropriately managed in both patients with and without antidiabetic medications. IGF-1 over-suppression may be observed in a few patients and requires appropriate dose reduction of pasireotide; nevertheless, IGF-1 may still remain low.
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